Trials of colchicine for COVID-19: Data Byte

Phase III data from the Montreal Heart Institute suggests colchicine could serve as an oral alternative to IV-infused mAbs for COVID-19 in the outpatient setting, but more data are needed.

The COLCORONA trial did not meet its primary endpoint of lowering the risk of COVID-19 death or hospitalization vs. placebo among the 4,488 patients in the trial. However, in the 4,159 patients who tested positive for SARS-CoV-2 by PCR, the difference between the treatment and placebo groups was statistically significant, and hospitalizations, need for mechanical ventilation and mortality fell by 25%, 50% and 44%, respectively. ...